BR9709086A - Inibidores de metaloproteinase de matriz composição tendo atividade inibitoria de metaloprotease de matriz processos para inibir atividade de metaloprotease de matriz em um mamífero e para tratar um mamífero - Google Patents
Inibidores de metaloproteinase de matriz composição tendo atividade inibitoria de metaloprotease de matriz processos para inibir atividade de metaloprotease de matriz em um mamífero e para tratar um mamíferoInfo
- Publication number
- BR9709086A BR9709086A BR9709086A BR9709086A BR9709086A BR 9709086 A BR9709086 A BR 9709086A BR 9709086 A BR9709086 A BR 9709086A BR 9709086 A BR9709086 A BR 9709086A BR 9709086 A BR9709086 A BR 9709086A
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- processes
- matrix
- matrix metalloprotease
- treat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/04—1,2,3-Triazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64849396A | 1996-05-15 | 1996-05-15 | |
PCT/US1997/007976 WO1997043239A1 (en) | 1996-05-15 | 1997-05-12 | Inhibition of matrix metalloproteases by 2-substituted-4-(4-substitutedphenyl)-4-oxobutyric acids |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9709086A true BR9709086A (pt) | 1999-08-03 |
Family
ID=24601014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9709086A BR9709086A (pt) | 1996-05-15 | 1997-05-12 | Inibidores de metaloproteinase de matriz composição tendo atividade inibitoria de metaloprotease de matriz processos para inibir atividade de metaloprotease de matriz em um mamífero e para tratar um mamífero |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP0923530B1 (pt) |
JP (1) | JP3354942B2 (pt) |
CN (1) | CN1100748C (pt) |
AR (1) | AR007098A1 (pt) |
AT (1) | ATE275123T1 (pt) |
AU (1) | AU714207B2 (pt) |
BR (1) | BR9709086A (pt) |
CA (1) | CA2254731C (pt) |
CO (1) | CO5011061A1 (pt) |
DE (1) | DE69730508T2 (pt) |
DK (1) | DK0923530T3 (pt) |
ES (1) | ES2227696T3 (pt) |
HK (1) | HK1021897A1 (pt) |
HR (1) | HRP970244B1 (pt) |
ID (1) | ID17291A (pt) |
MY (1) | MY132463A (pt) |
PA (1) | PA8429701A1 (pt) |
PE (1) | PE66898A1 (pt) |
PT (1) | PT923530E (pt) |
SV (1) | SV1997000036A (pt) |
TN (1) | TNSN97083A1 (pt) |
TW (1) | TW539672B (pt) |
WO (1) | WO1997043239A1 (pt) |
YU (1) | YU18597A (pt) |
ZA (1) | ZA974030B (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925637A (en) * | 1997-05-15 | 1999-07-20 | Bayer Corporation | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids |
US6288063B1 (en) | 1998-05-27 | 2001-09-11 | Bayer Corporation | Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors |
EP1031349A1 (en) * | 1999-02-25 | 2000-08-30 | Bayer Aktiengesellschaft | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases |
GB9922710D0 (en) * | 1999-09-24 | 1999-11-24 | Bayer Ag | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis |
PA8539401A1 (es) * | 2001-02-14 | 2002-10-28 | Warner Lambert Co | Quinazolinas como inhibidores de mmp-13 |
JP2004359546A (ja) * | 2001-03-15 | 2004-12-24 | Ono Pharmaceut Co Ltd | ヒドロキサム酸誘導体、それらの非毒性塩およびそれらのプロドラッグ体を有効成分として含有する、固形癌の予防および/または治療剤 |
WO2002074298A1 (fr) * | 2001-03-21 | 2002-09-26 | Ono Pharmaceutical Co., Ltd. | Inhibiteurs de production d'il-6 |
KR101405823B1 (ko) * | 2007-12-24 | 2014-06-12 | 주식회사 케이티앤지생명과학 | 녹내장의 치료 및 예방을 위한 약제 조성물 |
KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
AU2009283195A1 (en) * | 2008-08-18 | 2010-02-25 | Yale University | MIF modulators |
US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
WO2015150350A1 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren zur behandlung von atemwegserkrankungen |
WO2015150363A1 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
US20170119776A1 (en) | 2014-04-03 | 2017-05-04 | Bayer Pharma Aktiengesellschaft | Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof |
CN113979992B (zh) * | 2021-11-19 | 2022-06-24 | 西安欧得光电材料有限公司 | 一种3-取代二苯并噻吩及其合成方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR970700652A (ko) * | 1994-01-22 | 1997-02-12 | 포올 리틀우드 | 금속단백질 분해효소 억제제 |
-
1997
- 1997-05-09 CO CO97025174A patent/CO5011061A1/es unknown
- 1997-05-09 HR HR970244A patent/HRP970244B1/xx not_active IP Right Cessation
- 1997-05-09 ZA ZA9704030A patent/ZA974030B/xx unknown
- 1997-05-09 MY MYPI97002043A patent/MY132463A/en unknown
- 1997-05-09 TN TNTNSN97083A patent/TNSN97083A1/fr unknown
- 1997-05-12 YU YU18597A patent/YU18597A/sh unknown
- 1997-05-12 AT AT97926455T patent/ATE275123T1/de not_active IP Right Cessation
- 1997-05-12 CN CN97196454A patent/CN1100748C/zh not_active Expired - Fee Related
- 1997-05-12 EP EP97926455A patent/EP0923530B1/en not_active Expired - Lifetime
- 1997-05-12 WO PCT/US1997/007976 patent/WO1997043239A1/en active IP Right Grant
- 1997-05-12 SV SV1997000036A patent/SV1997000036A/es not_active Application Discontinuation
- 1997-05-12 AR ARP970101978A patent/AR007098A1/es unknown
- 1997-05-12 PE PE1997000365A patent/PE66898A1/es not_active Application Discontinuation
- 1997-05-12 BR BR9709086A patent/BR9709086A/pt not_active Application Discontinuation
- 1997-05-12 DE DE69730508T patent/DE69730508T2/de not_active Expired - Fee Related
- 1997-05-12 TW TW086106285A patent/TW539672B/zh not_active IP Right Cessation
- 1997-05-12 JP JP54100397A patent/JP3354942B2/ja not_active Expired - Fee Related
- 1997-05-12 DK DK97926455T patent/DK0923530T3/da active
- 1997-05-12 ES ES97926455T patent/ES2227696T3/es not_active Expired - Lifetime
- 1997-05-12 CA CA002254731A patent/CA2254731C/en not_active Expired - Fee Related
- 1997-05-12 AU AU31220/97A patent/AU714207B2/en not_active Ceased
- 1997-05-12 PA PA19978429701A patent/PA8429701A1/es unknown
- 1997-05-12 PT PT97926455T patent/PT923530E/pt unknown
- 1997-05-14 ID IDP971611A patent/ID17291A/id unknown
-
2000
- 2000-02-10 HK HK00100770A patent/HK1021897A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
SV1997000036A (es) | 1998-07-20 |
ATE275123T1 (de) | 2004-09-15 |
ES2227696T3 (es) | 2005-04-01 |
WO1997043239A1 (en) | 1997-11-20 |
CN1225621A (zh) | 1999-08-11 |
PE66898A1 (es) | 1998-10-22 |
AU714207B2 (en) | 1999-12-23 |
ZA974030B (en) | 1998-02-19 |
CA2254731C (en) | 2004-07-20 |
ID17291A (id) | 1997-12-18 |
CN1100748C (zh) | 2003-02-05 |
EP0923530B1 (en) | 2004-09-01 |
DK0923530T3 (da) | 2005-01-03 |
AR007098A1 (es) | 1999-10-13 |
TNSN97083A1 (fr) | 2005-03-15 |
TW539672B (en) | 2003-07-01 |
HRP970244B1 (en) | 2005-06-30 |
EP0923530A1 (en) | 1999-06-23 |
CO5011061A1 (es) | 2001-02-28 |
AU3122097A (en) | 1997-12-05 |
PA8429701A1 (es) | 2000-05-24 |
DE69730508T2 (de) | 2005-09-29 |
HK1021897A1 (en) | 2000-07-14 |
DE69730508D1 (de) | 2004-10-07 |
YU18597A (sh) | 2001-12-26 |
MY132463A (en) | 2007-10-31 |
CA2254731A1 (en) | 1997-11-20 |
PT923530E (pt) | 2004-12-31 |
HRP970244A2 (en) | 1998-04-30 |
JP3354942B2 (ja) | 2002-12-09 |
JPH11510821A (ja) | 1999-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9709086A (pt) | Inibidores de metaloproteinase de matriz composição tendo atividade inibitoria de metaloprotease de matriz processos para inibir atividade de metaloprotease de matriz em um mamífero e para tratar um mamífero | |
NO972307D0 (no) | Matriksmetallproteaseinhibitorer | |
AR009356A1 (es) | Compuesto de 1-4 heterociclico, inhibidor de la metaloproteasa y su uso para preparar una composicion farmaceutica y para prevenir o tratar una enfermedad asociada con la actividad de la metalo proteasa y la caquexia | |
ATE224364T1 (de) | Beta-sulfonamido hydroxamsäure als matrix metalloproteinase und als tace inhibitoren | |
ATE257151T1 (de) | Hydroxamsäure-derivate als matrix metalloproteinaseinhibitoren | |
BR9711988A (pt) | Inibidores de metaloproteinase de matriz e seus empregos terap-uticos | |
DE69803592T2 (de) | Kristallisationshemmung in transdermalen vorrichtungen | |
AR002859A1 (es) | Método y dispositivo para maquinar electroquimicamente | |
HK1011536A1 (en) | Alpha-substituted arylsulphonamido hydroxamic acids as tnf-alpha and matrix metalloproteinase inhibitors | |
DE69815716D1 (de) | Schlüssel zum verdrehen von sechseckigen muttern oder bolzen | |
NO20001323D0 (no) | Dipeptid-apoptose inhibitorer og deres anvendelse | |
ATE223909T1 (de) | Sulfamide-metalloprotease inhibitoren | |
PL337003A1 (en) | Caprophen selectively acting on cox-2 in treating pains and inflammatory states among dogs | |
DE59705298D1 (de) | Anlage zum automatischen zu- und abführen von rollen | |
GB9613547D0 (en) | Matrix metalloproteinase inhibitors | |
BR9709077A (pt) | Compostos inibindo metaloproteinase de matriz composição tendo atividade inibitória de metaloprotease de matriz processos para inibir atividade de metaloprotease de matriz e para tratar um mamífero | |
BR9407145A (pt) | Métodos para tratar apoptose e condições associadas | |
DE69824607D1 (de) | VERBESSERUNGEN AN ODER IN BEZIEHUNG ZU ÜBERWACHUNGs- UND ANANLYSE-SYSTEMEN | |
BR9709084A (pt) | Composto de inibição de metaloproteinase de matriz composição tendo atividade de inibição de metaloprotease de matriz e processos para inibir a atividade de metaloprotease de matriz em um mamífero e para tratar mamíferos | |
EP0722321A4 (en) | SULFOXIMIN AND SULFODIIMIN MATRIX METALLOPROTEINAS INHIBITORS | |
ZA979753B (en) | Use of inhibitors of the activity of retinoic acid for treating sensitive skins and/or the acute damage induced by UV radiation. | |
NO996234L (no) | Sprayformuleringer av antihyperalgesiske opiater og fremgangsmåte for behandling av topiske hyperalgesiske forhold og kløe med disse | |
NO20003506L (no) | Matriksmetallproteaseinhibitorer | |
IT1290564B1 (it) | Valvola idraulica di ritenuta del carico e di frenatura di discesa | |
BR9709075A (pt) | Compostos tendo atividade inibidora de metaloprotease de matriz composição tendo uma atividade inibidora de metaloprotease de matriz e processo para tratar uma condição mediada por metaloprotease de matriz em mamífero |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |